Arca
Skip to content

Intermediate Uveitis

Drug research and approvals for intermediate Uveitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 2 studies of intermediate Uveitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 2
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 2 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

6 in phase 3, 4 in phase 2, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Voclosporin
Phase 3 Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor
Methotrexate
Phase 3 Dihydrofolate reductase inhibitor
Mycophenolic acid
Phase 3 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Prednisone
Phase 3 Glucocorticoid receptor agonist
Fluocinolone acetonide
Phase 3 Glucocorticoid receptor agonist
Sirolimus
Phase 2 FK506-binding protein 1A inhibitor
Dexamethasone
Phase 2 Glucocorticoid receptor agonist
Piclidenoson
Phase 2 Adenosine A3 receptor agonist
Tesidolumab
Phase 2 Complement C5 binding agent
Tocilizumab
Phase 1 Interleukin-6 receptor alpha subunit inhibitor

How Its Trials Ended

31 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 16 whose ending is known, 56% met their primary endpoint, 0% missed it and 44% stopped early.

  • Completed, result not reported1032%
  • Met its primary endpoint929%
  • Stopped: other or unclear413%
  • Status unknown310%
  • Ongoing26%
  • Stopped: sponsor or business decision26%
  • Stopped: safety13%

Trials Authorized in Canada

Newest first; search them all in Canada trials
Sep 3, 2026A phase 2b, randomized, double-masked, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with active noninfectious…MK-7240 (tulisokibart) / prednisoneMerck & Co. (MSD)Pending
Jul 25, 2013A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of subjects with non-infectious intermediate,…GevokizumabServierOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Nov 4, 2011SirolimusTreatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and…Santen Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.